Mumbai-based Ajanta Pharma Limited has launched Tadalis (Tadalafil) for the management of erectile dysfunction (ED or impotence) in men. Tadalafil (Tadalis), the latest of the Phosphodiesterase (PDE5) inhibitor, has two times faster onset of action compared to sildenafil citrate and can facilitate up to 36 hours of sexual activity, according to a company release.

Tadalafil has been licensed for usage by the USFDA and is widely available in the United States and all across the European Union where it is popularly known as "Weekend Pill". The safety and effectiveness of Tadalis has been confirmed in randomised, placebo-controlled trials involving more than 4000 men with erectile dysfunction associated with diabetes mellitus or following prostatectomy. Remarkable improvement in sexual activity has been demonstrated within just 30 minutes of dosing of Tadalis with efficacy maintained up to 36 hours as confirmed in these multicentric trials.

Due to its high selectivity for the PDE5 isozyme, Tadalafil offers the highest degree of safety for patients with diabetes, hypertension and cancer as clinically proven in long-term studies. Tadalafil has absolutely no interactions with food or alcohol, which ensures better patient compliance.

The total size of the market for ED management products, globally, is worth more than USD 1 billion (Rs.5,000 crore) with Indian market estimates at about USD 22 million (Rs.100 crore). The market is growing at 32 per cent.

Ajanta Pharma has introduced novel therapies aimed to address the problem of erectile dysfunction. Kamagra (sildenafil citrate), one of the most popular brands of Ajanta is making rapid strides globally due to its wide acceptance by the medical fraternity in domestic as well as international markets.